AbbVie licenses Nxera oral inflammatory bowel disease drug in agreement worth up to $1.47 billion

AbbVie has secured exclusive worldwide rights to Nxera Pharma's investigational oral EP4 receptor agonist NXE0033744 for inflammatory bowel disease in a licensing agreement potentially worth $1.47 billion.

The transaction announced on 4 November 2026 provides Nxera with $100 million upfront and eligibility for up to $1.37 billion in development and commercial milestones plus tiered royalties, giving AbbVie responsibility for further development and commercialisation of the gut-targeted small molecule.

Discovered using Nxera's NxWave platform, NXE0033744 has completed Phase I studies including evaluation in a cohort with ulcerative colitis, but remains investigational, while completion of the licensing transaction is subject to customary antitrust clearance.

Field	Content
Article Type	Deals
Company	AbbVie
Licensing Partner	Nxera Pharma
Deal Type	Exclusive worldwide licence agreement
Announcement Date	4 November 2026
Transaction Status	Announced; subject to customary antitrust clearance
Licensed Asset	NXE0033744
Drug Class	EP4 receptor agonist
Modality	Oral small-molecule therapeutic
Administration Route	Oral
Therapeutic Area	Gastroenterology; inflammatory bowel disease
Target Indication	Inflammatory bowel disease
Clinical Population Studied	Phase I programme included a cohort with ulcerative colitis
Development Stage	Phase I completed
Discovery Platform	Nxera NxWave
Drug Design Focus	Gut-targeted EP4 receptor agonism
Maximum Potential Deal Value	$1.47 billion excluding royalties
Upfront Payment	$100 million
Potential Milestone Payments	Up to $1.37 billion
Milestone Categories	Development and commercial
Royalty Structure	Tiered royalties; rates not specified in supplied summary
Development Rights	AbbVie receives worldwide development rights
Commercialisation Rights	AbbVie receives worldwide commercialisation rights
Geographic Scope	Worldwide
Regulatory Status	Investigational; not approved
Transaction Conditions	Customary antitrust clearance
What Happened	AbbVie entered an exclusive global licence agreement for Nxera's investigational EP4 receptor agonist NXE0033744.
Why It Matters	The agreement adds a differentiated oral inflammatory bowel disease candidate to AbbVie's development pipeline and validates Nxera's discovery platform through a major pharmaceutical partnership.
Strategic Rationale	Advance a gut-targeted oral therapeutic for inflammatory bowel disease using AbbVie's global clinical development and commercial capabilities.
Financial Clarification	The $1.47 billion potential value comprises $100 million upfront and up to $1.37 billion in contingent milestones, excluding royalties.
Key Takeaway	AbbVie has agreed to license a Phase I-completed investigational IBD candidate with significant milestone-based consideration.
What to Watch	Antitrust clearance, subsequent clinical development, efficacy and safety results, regulatory submissions and milestone payments.
Primary Source	Nxera Pharma
Primary Source URL	https://rss.globenewswire.com/news-release/2026/11/04/3395033/0/en/nxera-pharma-enters-into-global-license-agreement-with-abbvie-for-nxe0033744-a-novel-ep4-receptor-agonist-for-inflammatory-bowel-disease.html
Relevant Date	4 November 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com